PMC:7321036 / 44470-47325
Annnotations
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T170 | 33-255 | SO:0000855 | denotes | or SARS-CoV-2 infection, kinase inhibitors were mapped to the most differentially regulated kinase activities (Figure 7 A) and to specific phosphorylation sites (Table S8; STAR Methods). This resulted in a list of 87 drugs |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T364 | 432-436 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T365 | 794-802 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T366 | 977-981 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T367 | 1386-1391 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T368 | 1550-1558 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T369 | 1590-1594 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T370 | 1674-1679 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T371 | 1763-1770 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T372 | 2084-2089 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T373 | 2265-2269 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T374 | 2270-2286 | Body_part | denotes | epithelial cells | http://purl.org/sig/ont/fma/fma66768 |
T375 | 2281-2286 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T376 | 2388-2391 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T377 | 2567-2571 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T378 | 2714-2719 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T16 | 2265-2269 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T219 | 36-44 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T220 | 47-56 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T221 | 205-209 | Disease | denotes | STAR | http://purl.obolibrary.org/obo/MONDO_0010408 |
T222 | 690-698 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T223 | 1168-1176 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T224 | 1276-1284 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T225 | 1287-1296 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T226 | 1456-1464 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T227 | 1467-1476 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T228 | 2229-2237 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T229 | 2240-2249 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T230 | 2344-2352 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T231 | 2355-2364 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T232 | 2479-2487 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T233 | 2814-2822 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T234 | 2825-2834 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T535 | 132-142 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activities |
T536 | 153-154 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T537 | 237-238 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T538 | 311-318 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
T539 | 432-436 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T540 | 452-453 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T541 | 563-570 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
T542 | 742-748 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
T543 | 791-793 | http://purl.obolibrary.org/obo/CLO_0008192 | denotes | NP |
T544 | 977-987 | http://purl.obolibrary.org/obo/CLO_0000031 | denotes | cell lines |
T545 | 989-993 | http://purl.obolibrary.org/obo/CLO_0009524 | denotes | Vero |
T546 | 989-993 | http://purl.obolibrary.org/obo/CLO_0050515 | denotes | Vero |
T547 | 1006-1010 | http://purl.obolibrary.org/obo/CLO_0001601 | denotes | A549 |
T548 | 1006-1010 | http://purl.obolibrary.org/obo/CLO_0050025 | denotes | A549 |
T549 | 1006-1010 | http://purl.obolibrary.org/obo/CLO_0054264 | denotes | A549 |
T550 | 1006-1010 | http://purl.obolibrary.org/obo/CLO_0054265 | denotes | A549 |
T551 | 1006-1010 | http://purl.obolibrary.org/obo/CLO_0054266 | denotes | A549 |
T552 | 1006-1010 | http://purl.obolibrary.org/obo/CLO_0054267 | denotes | A549 |
T553 | 1006-1010 | http://purl.obolibrary.org/obo/CLO_0054268 | denotes | A549 |
T554 | 1006-1010 | http://purl.obolibrary.org/obo/CLO_0054269 | denotes | A549 |
T555 | 1084-1086 | http://purl.obolibrary.org/obo/CLO_0008933 | denotes | S5 |
T556 | 1190-1191 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T557 | 1250-1258 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T558 | 1375-1376 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | B |
T559 | 1378-1391 | http://purl.obolibrary.org/obo/CLO_0051719 | denotes | Vero E6 cells |
T560 | 1481-1483 | http://purl.obolibrary.org/obo/CLO_0001382 | denotes | 48 |
T561 | 1547-1549 | http://purl.obolibrary.org/obo/CLO_0008192 | denotes | NP |
T562 | 1590-1594 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T563 | 1662-1663 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | B |
T564 | 1666-1679 | http://purl.obolibrary.org/obo/CLO_0051719 | denotes | Vero E6 cells |
T565 | 1828-1829 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T566 | 1896-1904 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T567 | 1917-1926 | http://purl.obolibrary.org/obo/SO_0000418 | denotes | signaling |
T568 | 2072-2073 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | B |
T569 | 2076-2089 | http://purl.obolibrary.org/obo/CLO_0051719 | denotes | Vero E6 cells |
T570 | 2255-2259 | http://purl.obolibrary.org/obo/CLO_0001601 | denotes | A549 |
T571 | 2255-2259 | http://purl.obolibrary.org/obo/CLO_0050025 | denotes | A549 |
T572 | 2255-2259 | http://purl.obolibrary.org/obo/CLO_0054264 | denotes | A549 |
T573 | 2255-2259 | http://purl.obolibrary.org/obo/CLO_0054265 | denotes | A549 |
T574 | 2255-2259 | http://purl.obolibrary.org/obo/CLO_0054266 | denotes | A549 |
T575 | 2255-2259 | http://purl.obolibrary.org/obo/CLO_0054267 | denotes | A549 |
T576 | 2255-2259 | http://purl.obolibrary.org/obo/CLO_0054268 | denotes | A549 |
T577 | 2255-2259 | http://purl.obolibrary.org/obo/CLO_0054269 | denotes | A549 |
T578 | 2265-2286 | http://purl.obolibrary.org/obo/CL_0000082 | denotes | lung epithelial cells |
T579 | 2425-2430 | http://purl.obolibrary.org/obo/OGG_0000000002 | denotes | genes |
T580 | 2434-2438 | http://purl.obolibrary.org/obo/CLO_0001601 | denotes | A549 |
T581 | 2434-2438 | http://purl.obolibrary.org/obo/CLO_0050025 | denotes | A549 |
T582 | 2434-2438 | http://purl.obolibrary.org/obo/CLO_0054264 | denotes | A549 |
T583 | 2434-2438 | http://purl.obolibrary.org/obo/CLO_0054265 | denotes | A549 |
T584 | 2434-2438 | http://purl.obolibrary.org/obo/CLO_0054266 | denotes | A549 |
T585 | 2434-2438 | http://purl.obolibrary.org/obo/CLO_0054267 | denotes | A549 |
T586 | 2434-2438 | http://purl.obolibrary.org/obo/CLO_0054268 | denotes | A549 |
T587 | 2434-2438 | http://purl.obolibrary.org/obo/CLO_0054269 | denotes | A549 |
T588 | 2453-2454 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T589 | 2567-2571 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T590 | 2693-2697 | http://purl.obolibrary.org/obo/CLO_0009524 | denotes | Vero |
T591 | 2693-2697 | http://purl.obolibrary.org/obo/CLO_0050515 | denotes | Vero |
T592 | 2704-2708 | http://purl.obolibrary.org/obo/CLO_0001601 | denotes | A549 |
T593 | 2704-2708 | http://purl.obolibrary.org/obo/CLO_0050025 | denotes | A549 |
T594 | 2704-2708 | http://purl.obolibrary.org/obo/CLO_0054264 | denotes | A549 |
T595 | 2704-2708 | http://purl.obolibrary.org/obo/CLO_0054265 | denotes | A549 |
T596 | 2704-2708 | http://purl.obolibrary.org/obo/CLO_0054266 | denotes | A549 |
T597 | 2704-2708 | http://purl.obolibrary.org/obo/CLO_0054267 | denotes | A549 |
T598 | 2704-2708 | http://purl.obolibrary.org/obo/CLO_0054268 | denotes | A549 |
T599 | 2704-2708 | http://purl.obolibrary.org/obo/CLO_0054269 | denotes | A549 |
T600 | 2714-2719 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T300 | 65-75 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T301 | 201-203 | Chemical | denotes | S8 | http://purl.obolibrary.org/obo/CHEBI_29385 |
T302 | 250-255 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T303 | 353-358 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T304 | 571-580 | Chemical | denotes | molecules | http://purl.obolibrary.org/obo/CHEBI_25367 |
T305 | 717-722 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T306 | 753-762 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T307 | 791-793 | Chemical | denotes | NP | http://purl.obolibrary.org/obo/CHEBI_50803|http://purl.obolibrary.org/obo/CHEBI_53793|http://purl.obolibrary.org/obo/CHEBI_73425 |
T310 | 915-920 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T311 | 1084-1086 | Chemical | denotes | S5 | http://purl.obolibrary.org/obo/CHEBI_29386 |
T312 | 1097-1099 | Chemical | denotes | S8 | http://purl.obolibrary.org/obo/CHEBI_29385 |
T313 | 1200-1210 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T314 | 1359-1363 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T315 | 1409-1419 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T316 | 1526-1530 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T317 | 1547-1549 | Chemical | denotes | NP | http://purl.obolibrary.org/obo/CHEBI_50803|http://purl.obolibrary.org/obo/CHEBI_53793|http://purl.obolibrary.org/obo/CHEBI_73425 |
T320 | 1647-1649 | Chemical | denotes | SD | http://purl.obolibrary.org/obo/CHEBI_74807 |
T321 | 1706-1715 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T322 | 1763-1770 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T323 | 1939-1944 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T324 | 2044-2056 | Chemical | denotes | gilteritinib | http://purl.obolibrary.org/obo/CHEBI_145372 |
T325 | 2107-2120 | Chemical | denotes | AXL inhibitor | http://purl.obolibrary.org/obo/CHEBI_62434 |
T326 | 2111-2120 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T327 | 2121-2133 | Chemical | denotes | gilteritinib | http://purl.obolibrary.org/obo/CHEBI_145372 |
T328 | 2153-2162 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T329 | 2194-2203 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T330 | 2316-2325 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T331 | 2746-2755 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T332 | 2776-2789 | Chemical | denotes | CDK inhibitor | http://purl.obolibrary.org/obo/CHEBI_82665 |
T333 | 2780-2789 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T321 | 58-75 | http://purl.obolibrary.org/obo/GO_0033673 | denotes | kinase inhibitors |
T322 | 125-142 | http://purl.obolibrary.org/obo/GO_0016301 | denotes | kinase activities |
T323 | 172-187 | http://purl.obolibrary.org/obo/GO_0016310 | denotes | phosphorylation |
T324 | 1139-1156 | http://purl.obolibrary.org/obo/GO_0033673 | denotes | Kinase Inhibitors |
T325 | 1193-1210 | http://purl.obolibrary.org/obo/GO_0033673 | denotes | Kinase inhibitors |
T326 | 1889-1904 | http://purl.obolibrary.org/obo/GO_0016301 | denotes | kinase activity |
T327 | 1917-1934 | http://purl.obolibrary.org/obo/GO_0007165 | denotes | signaling pathway |
T328 | 1917-1926 | http://purl.obolibrary.org/obo/GO_0023052 | denotes | signaling |
T329 | 2490-2507 | http://purl.obolibrary.org/obo/GO_0019079 | denotes | viral replication |
T330 | 2490-2507 | http://purl.obolibrary.org/obo/GO_0019058 | denotes | viral replication |
T331 | 2776-2789 | http://purl.obolibrary.org/obo/GO_0004861 | denotes | CDK inhibitor |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
929 | 1168-1178 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
931 | 1276-1296 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
935 | 1409-1419 | Chemical | denotes | remdesivir | MESH:C000606551 |
936 | 1456-1476 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
937 | 1383-1385 | CellLine | denotes | E6 | CVCL:4582 |
942 | 1779-1786 | Gene | denotes | CSNK2A2 | Gene:1459 |
943 | 1761-1762 | Gene | denotes | N | Gene:43740575 |
944 | 1716-1729 | Chemical | denotes | silmitasertib | |
945 | 1671-1673 | CellLine | denotes | E6 | CVCL:4582 |
950 | 1913-1916 | Gene | denotes | p38 | Gene:5594 |
951 | 1995-2001 | Gene | denotes | MAPK13 | Gene:5603 |
952 | 1982-1993 | Chemical | denotes | ralimetinib | |
953 | 2044-2056 | Chemical | denotes | gilteritinib | MESH:C000609080 |
962 | 2107-2110 | Gene | denotes | AXL | Gene:103234725 |
963 | 2143-2152 | Gene | denotes | MAPK11/14 | Gene:103223551 |
964 | 2187-2193 | Gene | denotes | MAPK13 | Gene:103221595 |
965 | 2204-2210 | Gene | denotes | MAPK13 | Gene:103221595 |
966 | 2121-2133 | Chemical | denotes | gilteritinib | MESH:C000609080 |
967 | 2163-2174 | Chemical | denotes | ralimetinib | |
968 | 2229-2249 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
969 | 2081-2083 | CellLine | denotes | E6 | CVCL:4582 |
975 | 2260-2264 | Gene | denotes | ACE2 | Gene:59272 |
976 | 2309-2315 | Gene | denotes | MAPK14 | Gene:1432 |
977 | 2326-2334 | Chemical | denotes | ARRY-797 | MESH:C000592910 |
978 | 2344-2364 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
979 | 2255-2259 | CellLine | denotes | A549 | CVCL:0023 |
985 | 2413-2416 | Gene | denotes | p38 | Gene:5594 |
986 | 2439-2443 | Gene | denotes | ACE2 | Gene:59272 |
987 | 2591-2595 | Gene | denotes | ACE2 | Gene:59272 |
988 | 2479-2489 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
989 | 2434-2438 | CellLine | denotes | A549 | CVCL:0023 |
994 | 2790-2800 | Chemical | denotes | dinaciclib | MESH:C553669 |
995 | 2814-2834 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
996 | 2698-2700 | CellLine | denotes | E6 | CVCL:4582 |
997 | 2704-2713 | CellLine | denotes | A549-ACE2 | CVCL:0023 |
999 | 2852-2854 | Gene | denotes | S6 | |
1006 | 1011-1015 | Gene | denotes | ACE2 | Gene:59272 |
1007 | 690-700 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1008 | 36-56 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
1009 | 846-854 | Disease | denotes | toxicity | MESH:D064420 |
1010 | 994-996 | CellLine | denotes | E6 | CVCL:4582 |
1011 | 1006-1010 | CellLine | denotes | A549 | CVCL:0023 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T293 | 0-219 | Sentence | denotes | To identify effective therapies for SARS-CoV-2 infection, kinase inhibitors were mapped to the most differentially regulated kinase activities (Figure 7 A) and to specific phosphorylation sites (Table S8; STAR Methods). |
T294 | 220-270 | Sentence | denotes | This resulted in a list of 87 drugs and compounds: |
T295 | 271-340 | Sentence | denotes | 10 FDA-approved, 53 undergoing clinical testing, and 24 pre-clinical. |
T296 | 341-545 | Sentence | denotes | Many of the drugs and compounds identified were reported to target several host kinases in cell-free assays at a minimum, but many have been observed to hit targets in cellular assays as well (Figure 7A). |
T297 | 546-701 | Sentence | denotes | We reasoned that testing molecules with both overlapping and unique targets would help specify the molecular targets of greatest importance for SARS-CoV-2. |
T298 | 702-1022 | Sentence | denotes | Here, 68 total drugs and compounds were tested for antiviral efficacy (via qRT-PCR, anti-NP antibody, plaque assay, and/or TCID50) and cellular toxicity at two different institutions (in New York [Mount Sinai, 25 drugs/compounds] and Paris [Institut Pasteur, 62]) and in two cell lines (Vero E6 [68] and A549-ACE2 [61]). |
T299 | 1023-1100 | Sentence | denotes | All pharmacological profiling results can be found in Figure S5 and Table S8. |
T300 | 1101-1188 | Sentence | denotes | Figure 7 Mapping Regulated Kinases to Kinase Inhibitors Identifies SARS-CoV-2 Therapies |
T301 | 1189-1297 | Sentence | denotes | (A) Kinase inhibitors (left) mapped to kinases (right) whose activity was regulated by SARS-CoV-2 infection. |
T302 | 1298-1373 | Sentence | denotes | Lines connecting them indicate known kinase targets for each drug/compound. |
T303 | 1374-1486 | Sentence | denotes | (B) Vero E6 cells pre-treated with remdesivir at the indicated doses, followed by SARS-CoV-2 infection for 48 h. |
T304 | 1487-1625 | Sentence | denotes | Percent viral titer compared with mock drug treatment (anti-NP antibody; red line, dots, and text) and cell viability (black) is depicted. |
T305 | 1626-1650 | Sentence | denotes | Error bars represent SD. |
T306 | 1651-1665 | Sentence | denotes | (C) As in (B). |
T307 | 1666-1730 | Sentence | denotes | Vero E6 cells were treated with the CK2 inhibitor silmitasertib. |
T308 | 1731-1864 | Sentence | denotes | Physical interactions between N protein and the CSNK2A2 and CSNK2B CK2 subunits were observed in a prior study (Gordon et al., 2020). |
T309 | 1865-2058 | Sentence | denotes | (D) Predicted increased kinase activity for the p38 signaling pathway and drugs/compounds targeting pathway members (ralimetinib, MAPK13-IN-1, and ARRY-797) and upstream drivers (gilteritinib). |
T310 | 2059-2075 | Sentence | denotes | (E–G) As in (B). |
T311 | 2076-2250 | Sentence | denotes | Vero E6 cells treated with the AXL inhibitor gilteritinib (E), the MAPK11/14 inhibitor ralimetinib (F), or the MAPK13 inhibitor MAPK13-IN-1 (G) prior to SARS-CoV-2 infection. |
T312 | 2251-2365 | Sentence | denotes | (H) A549-ACE2 lung epithelial cells were treated with the MAPK14 inhibitor ARRY-797 prior to SARS-CoV-2 infection. |
T313 | 2366-2590 | Sentence | denotes | (I) Small interfering RNA (siRNA) knockdown of p38 pathway genes in A549-ACE2 leads to a significant decrease in SARS-CoV-2 viral replication (red), as assessed by qRT-PCR in the absence of effects on cell viability (black). |
T314 | 2591-2682 | Sentence | denotes | ACE2 and non-targeting siRNAs are included as positive and negative controls, respectively. |
T315 | 2683-2835 | Sentence | denotes | (J and K) Vero E6 or A549-ACE2 cells were treated with PIKFYVE inhibitor apilimod (J) or the CDK inhibitor dinaciclib (K) prior to SARS-CoV-2 infection. |
T316 | 2836-2855 | Sentence | denotes | See also Figure S6. |